teclistamab,elranatamab
pfizer,janssen,genmab
['mmsm', 'magnestismm-3', 'elranatamab', 'majestec-1', 'teclistamab']
bi-specifics proof of concept with amg420 (bite). teclistamab 1st approved bi-specific with impressive orr, pfs. infection signal 76%. one of many bcma targeted therapies being evaluated. #ash22 #imfash22 #mmsm 
Hematology is in my ??. Posts are mine. Mayo Clinic Associate, Asst Prof, BMT RNCC, RN Navigator, emeritus. IMF NLB. MM KOL. Patient educator & advocate.